Desire enhancer
PT-141
May help support sexual desire via nasal spray.
How it works
PT-141
At a glance
- The only treatment in our lineup that works on sexual desire itself, through brain pathways, not blood flow
- Its active ingredient, bremelanotide, is FDA approved under the brand name Vyleesi® (2019) for low sexual desire in premenopausal women
- Ours is a compounded nasal spray, prescribed off-label, including for men
- Honest evidence status: the desire mechanism is real and FDA-recognized; data for the nasal spray form and for use in men are limited, and we say so
- Prescribed by a US-licensed physician, with clinician review before anything ships
What it is
PT-141 (bremelanotide) is fundamentally different from every ED pill. Sildenafil and tadalafil work below the waist, on blood vessels. PT-141 works above the neck: it activates melanocortin receptors in the brain, the signaling system involved in sexual arousal and desire. Its active ingredient earned FDA approval in 2019 under the brand name Vyleesi®, as an injectable treatment for hypoactive sexual desire disorder in premenopausal women, making it one of the few compounds ever approved for desire rather than mechanics. Ours is a compounded nasal spray version, prescribed off-label after a licensed clinician reviews your intake, including for men whose issue is wanting to, not being able to.
How it works
Sexual desire starts in the brain, in circuits the melanocortin system helps regulate. PT-141 stimulates those receptors directly. In practical terms, users describe it not as a mechanical response but as interest showing up again. It is taken as a nasal spray roughly 45 minutes to an hour before intimacy, works independently of blood-flow mechanics, and can be combined with a PDE5 medication when both desire and mechanics need support; your clinician will advise on combinations.
What the research shows
We separate what is proven from what is not. Proven: bremelanotide's effect on desire was demonstrated in the clinical trials behind its FDA approval, where about 25% of women experienced a meaningful increase in desire versus 17% on placebo, a real but modest effect. Its side effect profile is also well mapped. Not proven: large trials of the nasal spray form, and formal efficacy trials in men, do not exist; use in men rests on the shared biology of the melanocortin system, earlier research that included men, and clinical experience. If you want a guarantee, this molecule cannot offer one. What it offers is the only pathway to desire that regulators have ever signed off on, in a more convenient form.
What to expect
Take the spray about 45 minutes to an hour ahead. Effects are episodic, per use, not cumulative, and individual response varies more than with the blood-flow medications: some users respond strongly, some moderately, some not at all. We suggest judging it over several uses at your clinician's recommended dose, and being straight with yourself about whether it earns its price for you.
Side effects and who it's not for
The most common side effect by far is nausea, which affected up to 40% of users in the injectable trials, along with flushing and headache; the nasal spray can also cause nasal irritation, and tends to be gentler on the stomach in clinical experience. PT-141 can cause a small, temporary rise in blood pressure after each dose, which is why it is not appropriate for people with uncontrolled high blood pressure or known cardiovascular disease. A rare effect with frequent use is darkening of patches of skin. Your clinician screens for all of this during review.
FAQ
How is this different from Viagra® or the pills?
The pills improve blood flow so that arousal can become an erection; they do nothing for whether you feel like it. PT-141 targets the feeling-like-it part, in the brain. Different problem, different tool, and for some men the two are combined under clinician guidance.
Does it work for men?
The desire mechanism is the same in both sexes, earlier bremelanotide research included men, and clinicians have used it off-label in men for years. But we will not pretend trial-grade proof exists, because it does not. You are trying a biologically plausible, FDA-recognized mechanism in a population where formal data are thin, and your own response is the measure that matters.
Why a nasal spray instead of the injection?
Convenience, mainly. The FDA-approved product is an autoinjector; compounding pharmacies produce the spray for people who prefer needle-free use. The spray form has not been through its own large trials, which is part of why clinician oversight comes with it.
Why is it more expensive than the pills?
Different molecule, different manufacturing. The pills are mass-produced generics; PT-141 is a compounded peptide from a US compounding pharmacy, third-party tested by batch, with physician review and supervision included in the price. Longer plans bring the monthly price down.
Does insurance cover this?
No. In our telehealth setup, insurance coverage is unfortunately not possible, so you pay for your treatment directly, with the full service included.
What happens if I stop?
Nothing to unwind. PT-141 is used per episode, not continuously; there is no dependence, no taper, and no rebound. Use it when you want its effect.
All trademarks are the property of their respective owners. This product is not affiliated with, endorsed by, or sponsored by the makers of the brand-name medications referenced above.
-
Clinician guided
Every protocol is reviewed by a licensed provider before fulfillment.
-
Discreet delivery
Medications ship in plain packaging with free expedited options where available.
-
Ongoing care
Stay supported with check-ins, dosage guidance, and care team messaging.